Skip to main content
padlock icon - secure page this page is secure

Ciclosporin A as a Reversal Agent Against Concurrent Multidrug Resistance in Tumors with Nanobubbles

Buy Article:

$106.92 + tax (Refund Policy)

The purpose of this work was to challenge the multidrug resistance (MDR) in tumor through nanobubbles (NB) co-loaded reversal agent and chemotherapeutic drug layer by layer. The core/shell NB structure contains Doxorubicin (Dox) as anticancer drug in the core and Ciclosporin A (CsA), a cyclic polypeptide composed of 11 amino acids, as a reversal agent in the shell. The drug was designed to work against concurrent MDR processes and was defined as CsA/Dox/NB. HL60/ADM cells with typical high expression of multidrug resistance associated protein 1 (MRP1) were assessed by flow cytometer, 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays, and Western blot analysis to observe the in vitro and in vivo anticancer efficacy and reversal ability of MDR. Results demonstrated that the function and expression of MRP1 could be successfully inhibited by CsA as a reversal agent from the pharmaceutical preparation, leading to dramatic increase of intracellular concentration of Dox. The accumulation of anticancer drug in the MDR cancer cells enhanced inhibition of cell proliferation through G2/M arrest and tumor growth of nude mice xenograft model. It was therefore concluded that the CsA/Dox/NB can be a promising drug candidate in overcoming tumor MDR.
No Reference information available - sign in for access.
No Citation information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics


Document Type: Research Article

Publication date: January 1, 2018

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more